Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Michalina MontañoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0003-2872-1929
Adrienne E ShapiroVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0002-3106-1258
Bridget M WhitneyDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0002-3738-5704
Laura BamfordDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.ORCID 0009-0005-7192-6075
Greer BurkholderDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0001-7185-3025
Edward R CachayDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.ORCID 0000-0002-2452-7558
Katerina A ChristopoulosDivision of HIV, ID, and Global Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-8598-2191
Heidi M CraneDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0002-3308-7005
Joseph A C DelaneyDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0003-1771-1776
Joseph J EronDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-4938-0644
Rob J FredericksenDepartment of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0003-3936-7048
Peter W HuntDivision of Experimental Medicine, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-4571-4870
Jeffrey M JacobsonDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Jeanne C KerulyDepartments of Medicine and Epidemiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-8489-435X
H Nina KimDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0001-6710-9666
Kenneth H MayerFenway Health and Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, The Fenway Institute, Boston, Massachusetts, USA.ORCID 0000-0001-7460-733X
Richard D MooreDepartments of Medicine and Epidemiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8250-5069
Sonia NapravnikDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9032-3713
April PettitDivision of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-8832-0866
Michael S SaagDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0002-8866-1043
George A YendewaDivision of HIV, ID, and Global Medicine, University of California, San Francisco, California, USA.ORCID 0000-0003-4322-8577
Mari M KitahataDivision of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0002-5410-7175
Rachel A Bender IgnacioVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.ORCID 0000-0001-6167-1447
CFAR Network of Integrated Clinical Systems
Funding
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Savita Pahwa · 2007 to 2026
$33.8M
Tennessee CFAR: Implementation of Culturally Responsive Trauma-Informed Care with Youth with HIV in Memphis, TNP30AI110527 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Koethe · 2015 to 2026
$27.5M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
CFARNational Institute of Allergy and Infectious DiseasesNIAID NIH HHS K23 AI140918NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI036219NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI073961NIAID NIH HHS P30 AI094189NIAID NIH HHS P30 AI110527NIAID NIH HHS R24 AI067039NIDA NIH HHS U01 DA036935University of North Carolina Chapel Hill P30 AI50410University of WashingtonVanderbilt Univ
6 · The paper itself
Abstract
introductionSince its global reemergence in 2022, monkeypox (mpox) has demonstrated increased incidence and severity among people with human immunodeficiency virus (HIV [PWH]). Predictors of mpox diagnosis, vaccination, and outcomes among PWH are limited.
methodsWe included PWH with primary care visits after 1 January 2022 at 9 US sites participating in the Centers for AIDS Research Network of Integrated Clinic Systems Network. We identified mpox diagnosed between 1 June 2022 and 31 May 2023, through a combination of polymerase chain reaction result, diagnosis code, and/or tecovirimat receipt. We examined validated clinical diagnoses, laboratory results, vaccine data, and patient reported outcomes. We evaluated relative risks (RR) of mpox diagnosis, hospitalization, tecovirimat treatment, and vaccine receipt.
findingsAmong 19 777 PWH in care, 413 mpox cases (all male sex at birth) occurred (2.2 cases/100 person-years). Age <40 years, geographic region, Hispanic/Latine ethnicity, lack of antiretroviral therapy, detectable HIV viral load, and recent bacterial sexually transmitted infection predicted mpox diagnosis. PWH with CD4 200-349 cells/mm3 were most likely to be hospitalized (adjusted RR, 3.20; 95% confidence interval: 1.44-7.09) compared to CD4 ≥500, but half as likely as those with CD4 <200 to receive tecovirimat. Overall, smallpox/mpox vaccine effectiveness of ≥1 vaccine was 71% (adjusted RR, 0.29; 95% confidence interval: .14-.47) at preventing mpox, and 86% or better with CD4 ≥350 or HIV viral suppression. Non-Hispanic Black PWH were less likely to be vaccinated than other racial/ethnic identities.
interpretationPWH not on antiretroviral therapy or with unsuppressed HIV were more likely to be diagnosed with, and hospitalized for, mpox. Mpox/smallpox vaccine effectiveness was high, inclusive of those with low CD4 count and HIV viremia.
Indexed as
HIV InfectionsMpox, MonkeypoxVaccine EfficacyAdolescentAdultCohort StudiesFemaleHospitalizationHumansIncidenceMaleMiddle AgedUnited StatesYoung AdultdisparitiesepidemicepidemiologyHIVMpoxvaccine effectiveness
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort. · full record | OpenQuestion